Zunsemetinib free base · Synonyms: ATI-450 | (P)-ATI-450 | CDD450

Zunsemetinib is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 pathway inhibitor.

For research use only. Not for human or veterinary use.

Target MAPKAPK2 (MK2)

Research area Inflammation/Immunology

Purity >98% Stock Inquire

Data Sheet SDS COA

Zunsemetinib structure

CAS No.: 1640282-42-3

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
25 mg	USD 400.00	BP-02229-25mg	In stock	Get quote
50 mg	USD 550.00	BP-02229-50mg	In stock	Get quote
100 mg	USD 850.00	BP-02229-100mg	In stock	Get quote
250 mg	USD 1,200.00	BP-02229-250mg	In stock	Get quote
500 mg	USD 1,800.00	BP-02229-500mg	In stock	Get quote
1 g	USD 2,600.00	BP-02229-1g	In stock	Get quote

Need another size or custom synthesis? Request a quote.

Description

Zunsemetinib (ATI-450;CDD450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor.

Biological activity

Zunsemetinib (ATI-450;CDD450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor. Zunsemetinib can be used for the research of immuno-inflammatory diseases.

Identifiers

SMILES: FC1=CC(F)=CN=C1COC2=C(Cl)C(N(C3=CC(C4=NC(C(C)(C)O)=NC=C4)=NC=C3C)C(C)=C2)=O
InChIKey: FQPQMJULRZINPV-UHFFFAOYSA-N

Specifications

MW (average): 513.9240
Formula: C₂₅H₂₂ClF₂N₅O₃
CAS No.: 1640282-42-3
Physical state: Solid
Color: White to yellow
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20℃ 2 years; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO 100 mg/mL

In vitro: DMSO : 100 mg/mL

Documents

References

[1]. Zunsemetinib (ATI-450) – Investigational oral MK2 pathway inhibitor

[2]. Aclaris Therapeutics Announces ATI-450 (MK2 pathway Inhibitor) publication in Journal of Experimental Medicine

[3]. Wang C, et al. Selective inhibition of the p38α MAPK-MK2 axis inhibits inflammatory cues including inflammasome priming signals. J Exp Med. 2018;215(5):1315-1325.

Same research area

Search Inflammation/Immunology